Baird Reiterates Outperform, $100 Target On Medicines Co. As Firm Notes Inclisiran 'findings, while early, give us incremental optimism for the ongoing CV outcomes trial (CVOT) ORION-4, to demonstrate CV benefit with inclisiran'